Compare PRFX & NUWE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRFX | NUWE |
|---|---|---|
| Founded | 2007 | 1999 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7M | 2.9M |
| IPO Year | 2020 | N/A |
| Metric | PRFX | NUWE |
|---|---|---|
| Price | $0.89 | $2.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 95.3K | 33.8K |
| Earning Date | 02-27-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,167,999.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.48 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.61 | $1.71 |
| 52 Week High | $6.65 | $70.14 |
| Indicator | PRFX | NUWE |
|---|---|---|
| Relative Strength Index (RSI) | 49.84 | 43.76 |
| Support Level | $0.66 | $1.93 |
| Resistance Level | $0.74 | $2.09 |
| Average True Range (ATR) | 0.06 | 0.14 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 74.46 | 54.80 |
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.
Nuwellis Inc is a medical technology company focused on developing, manufacturing, and commercializing a medical device used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.